155 related articles for article (PubMed ID: 18363094)
1. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.
Peixoto A; Santos C; Rocha P; Pinheiro M; Príncipe S; Pereira D; Rodrigues H; Castro F; Abreu J; Gusmão L; Amorim A; Teixeira MR
Breast Cancer Res Treat; 2009 Mar; 114(1):31-8. PubMed ID: 18363094
[TBL] [Abstract][Full Text] [Related]
2. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
3. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation.
Peixoto A; Santos C; Pinheiro M; Pinto P; Soares MJ; Rocha P; Gusmão L; Amorim A; van der Hout A; Gerdes AM; Thomassen M; Kruse TA; Cruger D; Sunde L; Bignon YJ; Uhrhammer N; Cornil L; Rouleau E; Lidereau R; Yannoukakos D; Pertesi M; Narod S; Royer R; Costa MM; Lazaro C; Feliubadaló L; Graña B; Blanco I; de la Hoya M; Caldés T; Maillet P; Benais-Pont G; Pardo B; Laitman Y; Friedman E; Velasco EA; Durán M; Miramar MD; Valle AR; Calvo MT; Vega A; Blanco A; Diez O; Gutiérrez-Enríquez S; Balmaña J; Ramon y Cajal T; Alonso C; Baiget M; Foulkes W; Tischkowitz M; Kyle R; Sabbaghian N; Ashton-Prolla P; Ewald IP; Rajkumar T; Mota-Vieira L; Giannini G; Gulino A; Achatz MI; Carraro DM; de Paillerets BB; Remenieras A; Benson C; Casadei S; King MC; Teugels E; Teixeira MR
Breast Cancer Res Treat; 2011 Jun; 127(3):671-9. PubMed ID: 20652400
[TBL] [Abstract][Full Text] [Related]
4. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers.
Górski B; Debniak T; Jakubowska A; Cybulski C; Huzarski T; Byrski T; Złowocka E; Lubiński J
J Appl Genet; 2003; 44(3):419-23. PubMed ID: 12923317
[TBL] [Abstract][Full Text] [Related]
6. BRCA2 founder mutation in Slovenian breast cancer families.
Krajc M; De Grève J; Goelen G; Teugels E
Eur J Hum Genet; 2002 Dec; 10(12):879-82. PubMed ID: 12461697
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
8. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
[TBL] [Abstract][Full Text] [Related]
9. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
[TBL] [Abstract][Full Text] [Related]
11. Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain.
Campos B; Díez O; Odefrey F; Domènech M; Moncoutier V; Martínez-Ferrandis JI; Osorio A; Balmaña J; Barroso A; Armengod ME; Benítez J; Alonso C; Stoppa-Lyonnet D; Goldgar D; Baiget M
Hum Mutat; 2003 Apr; 21(4):452. PubMed ID: 12655574
[TBL] [Abstract][Full Text] [Related]
12. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
[TBL] [Abstract][Full Text] [Related]
13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
14. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.
Gutiérrez-Enríquez S; de la Hoya M; Martínez-Bouzas C; Sanchez de Abajo A; Ramón y Cajal T; Llort G; Blanco I; Beristain E; Díaz-Rubio E; Alonso C; Tejada MI; Caldés T; Diez O
Breast Cancer Res Treat; 2007 May; 103(1):103-7. PubMed ID: 17063271
[TBL] [Abstract][Full Text] [Related]
15. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
16. Origin and distribution of the BRCA2-8765delAG mutation in breast cancer.
Palomba G; Cossu A; Friedman E; Budroni M; Farris A; Contu A; Pisano M; Baldinu P; Sini MC; Tanda F; Palmieri G
BMC Cancer; 2007 Jul; 7():132. PubMed ID: 17640379
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families.
Gerdes AM; Cruger DG; Thomassen M; Kruse TA
Clin Genet; 2006 Feb; 69(2):171-8. PubMed ID: 16433698
[TBL] [Abstract][Full Text] [Related]
18. Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.
Konstantopoulou I; Rampias T; Ladopoulou A; Koutsodontis G; Armaou S; Anagnostopoulos T; Nikolopoulos G; Kamakari S; Nounesis G; Stylianakis A; Karanikiotis C; Razis E; Gogas H; Keramopoulos A; Gaki V; Markopoulos C; Skarlos D; Pandis N; Bei T; Arzimanoglou I; Fountzilas G; Yannoukakos D
Breast Cancer Res Treat; 2008 Feb; 107(3):431-41. PubMed ID: 17453335
[TBL] [Abstract][Full Text] [Related]
19. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
[TBL] [Abstract][Full Text] [Related]
20. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
